Cue Biopharma (CUE) to Release Quarterly Earnings on Monday

Cue Biopharma (NASDAQ:CUE) will be announcing its quarterly earnings data on Monday, April 8th.

Cue Biopharma Trading Up 3.9 %

Cue Biopharma stock opened at $1.85 on Friday. Cue Biopharma has a 12 month low of $1.70 and a 12 month high of $5.12. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.12. The stock has a market cap of $89.99 million, a P/E ratio of -1.55 and a beta of 2.02. The company’s fifty day simple moving average is $2.11 and its 200-day simple moving average is $2.35.

Institutional Investors Weigh In On Cue Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wolverine Trading LLC acquired a new stake in Cue Biopharma during the third quarter worth about $26,000. BNP Paribas Arbitrage SNC grew its holdings in shares of Cue Biopharma by 9,270.1% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 9,089 shares of the company’s stock worth $33,000 after purchasing an additional 8,992 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Cue Biopharma during the fourth quarter valued at approximately $37,000. Citigroup Inc. acquired a new position in shares of Cue Biopharma in the second quarter valued at $38,000. Finally, California State Teachers Retirement System bought a new position in Cue Biopharma in the second quarter worth $42,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on CUE. Jefferies Financial Group assumed coverage on Cue Biopharma in a research note on Wednesday, March 13th. They issued a “buy” rating and a $6.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $8.00 price target on shares of Cue Biopharma in a research note on Wednesday.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.